Evidence map›Paper›PMID 40124846›Full record

ArticleChemical engineering journal (Lausanne, Switzerland : 1996)2025

Distinct role of perlecan in mesenchymal tissue regeneration via genetic and epigenetic modification.

Bin Wang, Zhihua Lu, Gongming Gao, Elmira Mikaeiliagah, Lei Wang, Qingqing Yu, Zhuo Wang, Gangqing Hu, Song Chen, Xiaobing Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical engineering journal (Lausanne, Switzerland : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bin WangStem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, West Virginia University, Morgantown, WV, USA.
Zhihua LuStem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, West Virginia University, Morgantown, WV, USA.
Gongming GaoStem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, West Virginia University, Morgantown, WV, USA.
Elmira MikaeiliagahStem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, West Virginia University, Morgantown, WV, USA.
Lei WangDepartment of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.
Qingqing YuStem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, West Virginia University, Morgantown, WV, USA.
Zhuo WangStem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, West Virginia University, Morgantown, WV, USA.
Gangqing HuDepartment of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.
Song ChenDepartment of Orthopaedics, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.
Xiaobing ZhangHaihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical College, Tianjin, China.
Ming PeiStem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, West Virginia University, Morgantown, WV, USA.

Funding

Decellularized Matrix and Cartilage RegenerationR01AR067747 · NIAMS · WEST VIRGINIA UNIVERSITY · PI PEI, MING · 2016 to 2020
$1.7M
CRISPR-Cas9 Genome Edited MSCs to Target OA Cartilage RegenerationR56AR078846 · NIAMS · WEST VIRGINIA UNIVERSITY · PI PEI, MING · 2022 to 2022
$366k
NIAMS NIH HHS R01 AR067747NIAMS NIH HHS R56 AR078846
6 · The paper itself

Abstract

Perlecan (HSPG2), a key component of basement membrane proteins, plays a crucial role in tissue development and regeneration. However, its direct impact on mesenchymal tissue differentiation, mediated through both genetic modification (gain- and loss-of-function mutations) and epigenetic changes (matrix microenvironment alterations), remains underexplored. In this study, we utilized CRISPR/Cas9 to achieve knockout (KO) and overexpression (OE) of HSPG2 in human fetal nucleus pulposus stem/progenitor cells (NPSCs) and adult infrapatellar fat pad-derived stem cells (IPFSCs) to investigate perlecan's influence on mesenchymal differentiation. We also assessed the effects of decellularized extracellular matrix (dECM) derived from fetal NPSCs with modified HSPG2 expression on the proliferation and differentiation of adult NPSCs. Our findings demonstrate that HSPG2-KO enhance chondrogenic differentiation, while HSPG2-OE suppressed adipogenic differentiation in both fetal NPSCs and adult IPFSCs. Notably, dECM from HSPG2-OE fetal NPSCs significantly promoted chondrogenic differentiation in adult NPSCs, suggesting potential applications for perlecan in developing advanced biomaterials for cartilage regeneration.

Indexed as

CRISPR/Cas9dECMIPFSCMesenchymal differentiationNPSCPerlecan

Identifiers

PMID40124846
PMCPMC11928145

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.